Aquinox Pharmaceuticals and Vitalograph to Sponsor C0PD 2013

LONDON - Oct. 3, 2013 - PRLog -- Aquinox Pharmaceuticals, who will be sponsoring the event alongside Vitalograph, will be providing delegates with a unique insight into targeting SHIP1 activation and the role it plays in COPD and other inflammatory diseases. Stephen Shrewsbury, Senior VP of Clinical Development at Aquinox, who will be presenting the case study, commented:

"COPD is steadily growing as a cause of global death. Aquinox are focused on developing a novel drug which may provide physicians with a much needed effective oral treatment. Progress to date will be presented building on the data reported at the 2013 SMi’s COPD 2013 meeting”

Delegates will also have the opportunity to hear a keynote address by industry KOL, Sebastian Johnson, Professor of Respiratory Medicine from Imperial College London Sebastian will be discussing the aetiology of exacerbations.

A snap shot of attendees include  AstraZeneca, GSK, Glenmark Pharmaceuticals, Vectura, and Takeda.

SPEAKERS FOR COPD 2013 INCLUDE:

·         Sebastian Johnston, Professor of Respiratory Medicine, Imperial College London

·         Carol Astbury, Head of Early Global Development, Almirall

·         Ewan Walters, Medical Director, Teva UK Ltd

·         Iain Kilty, Respiratory Disease Area Lead, Pfizer

·         Jonathan Phillips, Principal Scientist, Amgen

·         Liz Hardaker, Investigator III, Novartis

·         Matthew Catley, Team Leader RIA, AstraZeneca

For further information on the event visit http://www.smi-online.co.uk

COPD: 16-17 OCT 2013

Marriott Hotel, Regents Park, London UK